PMC9792132_01
Imaging and pathological examination of the patient before treatment (tumor marked in red arrow). (A-C) Abdominal MRI revealed a soft tissue mass in the gastric cardia and multiple scattered nodules in the liver, (A) Coronal imaging of the lesion on liver, (B) Sagittal imaging of the lesion on liver, (C) Sagittal imaging of the lesion on gastric cardia. (D) Upper gastrointestinal endoscopy findings before treatment. The posterior wall of the cardia showed surrounding eminence and central ulcerative lesions with an area of 1.8 x 1.8 cm. (E) PET-CT showed uneven thickening of the gastric wall in the cardia area, as well as multiple nodules in the liver. (F-I) Pathological examination of gastric biopsy specimen confirmed moderately differentiated adenocarcinoma. (F) H&E, x 200. (G) Ki67, x 200. (H) P16, x100. (I) P53, x 100.
fimmu-13-1073094-g001.jpg
PMC9792132_04_fimmu-13-1073094-g001.jpg
f1
PMC9792132_02
PMC9792132_03
Imaging and pathological examination of the patient before treatment (tumor marked in red arrow). (A-C) Abdominal MRI revealed a soft tissue mass in the gastric cardia and multiple scattered nodules in the liver, (A) Coronal imaging of the lesion on liver, (B) Sagittal imaging of the lesion on liver, (C) Sagittal imaging of the lesion on gastric cardia. (D) Upper gastrointestinal endoscopy findings before treatment. The posterior wall of the cardia showed surrounding eminence and central ulcerative lesions with an area of 1.8 x 1.8 cm. (E) PET-CT showed uneven thickening of the gastric wall in the cardia area, as well as multiple nodules in the liver. (F-I) Pathological examination of gastric biopsy specimen confirmed moderately differentiated adenocarcinoma. (F) H&E, x 200. (G) Ki67, x 200. (H) P16, x100. (I) P53, x 100.
fimmu-13-1073094-g001.jpg
PMC9792132_04_fimmu-13-1073094-g001.jpg
f1
Imaging, pathological and clinical parameters of the patient following study design (tumor marked with red arrow). (A) The patient received a multimodal therapy comprised of SOX chemotherapy, anti-PD-1 therapy, and iNKT cell immunotherapy followed by surgical resection. The SOX regimen was administered every 21 days; Anti-PD-1 mAb was administered intravenously once every 21 days; iNKT cells were infused twice monthly. (B-D) Abdominal MRI revealed a decrease of the metastatic tumor in the liver and the lesion occupying the cardia region (after 2 cycles of treatment). (B) Coronal imaging of the lesion on liver, (C) Sagittal imaging of the lesion on liver, (D) Sagittal imaging of the lesion on gastric cardia. (E-G) Abdominal MRI revealed a further decrease of the largest metastatic tumor in the liver (after 6 cycles of treatment). (E) Coronal imaging of the lesion on liver, (F) Sagittal imaging of the lesion on liver, (G) Sagittal imaging of the lesion on gastric cardia. (H, I) The downward trend of CEA and CA-199 during treatment (CEA normal range, 0.0-5.0 ng/mL; CA199 normal range, 0.00-37.00 U/mL). (J-M) Pathological examination of gastric and liver biopsy specimen confirmed pCR after surgery. Gastric specimen (J, magnificationx40, K, magnificationx100); Liver specimen (L, magnificationx40, M, magnificationx100).
fimmu-13-1073094-g002.jpg
PMC9792132_04_fimmu-13-1073094-g002.jpg
f2
Pathological examination found no cancer cells in the primary or liver metastatic lesions, confirming a pCR ( Figures 2J-M ).
PMC9792132_04
Imaging and pathological examination of the patient before treatment (tumor marked in red arrow). (A-C) Abdominal MRI revealed a soft tissue mass in the gastric cardia and multiple scattered nodules in the liver, (A) Coronal imaging of the lesion on liver, (B) Sagittal imaging of the lesion on liver, (C) Sagittal imaging of the lesion on gastric cardia. (D) Upper gastrointestinal endoscopy findings before treatment. The posterior wall of the cardia showed surrounding eminence and central ulcerative lesions with an area of 1.8 x 1.8 cm. (E) PET-CT showed uneven thickening of the gastric wall in the cardia area, as well as multiple nodules in the liver. (F-I) Pathological examination of gastric biopsy specimen confirmed moderately differentiated adenocarcinoma. (F) H&E, x 200. (G) Ki67, x 200. (H) P16, x100. (I) P53, x 100.
fimmu-13-1073094-g001.jpg
PMC9792132_04_fimmu-13-1073094-g001.jpg
f1
Imaging, pathological and clinical parameters of the patient following study design (tumor marked with red arrow). (A) The patient received a multimodal therapy comprised of SOX chemotherapy, anti-PD-1 therapy, and iNKT cell immunotherapy followed by surgical resection. The SOX regimen was administered every 21 days; Anti-PD-1 mAb was administered intravenously once every 21 days; iNKT cells were infused twice monthly. (B-D) Abdominal MRI revealed a decrease of the metastatic tumor in the liver and the lesion occupying the cardia region (after 2 cycles of treatment). (B) Coronal imaging of the lesion on liver, (C) Sagittal imaging of the lesion on liver, (D) Sagittal imaging of the lesion on gastric cardia. (E-G) Abdominal MRI revealed a further decrease of the largest metastatic tumor in the liver (after 6 cycles of treatment). (E) Coronal imaging of the lesion on liver, (F) Sagittal imaging of the lesion on liver, (G) Sagittal imaging of the lesion on gastric cardia. (H, I) The downward trend of CEA and CA-199 during treatment (CEA normal range, 0.0-5.0 ng/mL; CA199 normal range, 0.00-37.00 U/mL). (J-M) Pathological examination of gastric and liver biopsy specimen confirmed pCR after surgery. Gastric specimen (J, magnificationx40, K, magnificationx100); Liver specimen (L, magnificationx40, M, magnificationx100).
fimmu-13-1073094-g002.jpg
PMC9792132_04_fimmu-13-1073094-g002.jpg
f2
Pathological examination found no cancer cells in the primary or liver metastatic lesions, confirming a pCR ( Figures 2J-M ).
PMC9792132_05